Why Is Alumis (ALMS) Stock Down -6% Today?
Key Takeaways
- ALMS shares fell roughly 6% in Wednesday's session, slipping to about $7.90 from a prior close of $8.40.
- The decline extends the sharp sell-off that began after the company's Phase 2b LUMUS trial in systemic lupus erythematosus (SLE) missed its primary and secondary endpoints.
- A wave of analyst target cuts and at least one downgrade has kept pressure on the clinical-stage biotech's valuation.
- Broader risk-off sentiment in speculative biotech names has compounded the stock's downside.
- Traders are now focused on the company's planned fourth-quarter 2026 NDA filing for its psoriasis program.
Opening Summary
Alumis Inc. (ALMS), a clinical-stage biopharmaceutical company developing oral TYK2 inhibitors for immune-mediated diseases, extended its recent slide on Wednesday, trading down approximately 6% to about $7.90 per share, versus a prior session close of $8.40. The move confirms continued downside momentum for the South San Francisco-based drug developer, whose stock has been under heavy selling pressure since the company disclosed that its lead candidate, envudeucitinib, failed to meet its primary and secondary endpoints in a mid-stage lupus trial. Markets attributed the latest leg lower primarily to lingering investor concern over the program's setback rather than any single new corporate announcement.
Post-Trial Fallout Weighs on Shares
The dominant catalyst behind the stock's slide remains the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus. Announced at the start of September, the study did not meet its primary or secondary endpoints in the overall trial population, a disappointment that erased more than half of the company's market value in a single session. Although a prespecified subgroup of patients with a high interferon gene signature (IFNGS-high) showed encouraging responses, investors have remained cautious, given that the broader efficacy miss raises questions about the drug's commercial path in a disease long considered a development graveyard.
Analyst Downgrades and Target Cuts
The negative readout triggered a flurry of revised estimates from Wall Street. Morgan Stanley lowered its price target to $29 from $39, while Wells Fargo cut its target to $25 from $51. Guggenheim downgraded the shares from buy to neutral, and several other firms trimmed their outlooks as they removed the lupus indication from their valuation models. This steady stream of downward revisions has kept ALMS under pressure, as institutional investors reassess the probability of success across the company's broader pipeline beyond its flagship psoriasis opportunity.
Sector and Market Context
The stock's decline also reflects broader caution in the speculative biotech segment, where clinical-stage companies remain especially sensitive to binary data readouts and rising financing concerns. With limited near-term revenue and a pipeline still in development, ALMS has traded as a high-beta, sentiment-driven name. Wednesday's selling occurred against a backdrop of uneven risk appetite across small- and mid-cap healthcare stocks, amplifying the downward drift in a stock that had already broken below prior support levels established before the lupus readout.
Market Context and Trading Activity
Trading in ALMS has remained notably heavier than the stock's pre-announcement baseline in recent sessions, reflecting elevated turnover as investors reposition following the clinical setback. The shares have drifted steadily lower over the past two weeks, with the price now well below both its 50-day and 200-day moving averages. The continued decline has pushed the stock toward the lower end of its recent trading range, underscoring the lack of buying conviction despite the company's insistence that its psoriasis program remains on track.
What Comes Next for ALMS
Investor attention now shifts to the company's regulatory milestones. Alumis has reiterated plans to submit a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis during the fourth quarter of 2026, following positive Phase 3 ONWARD data. The company is also pursuing regulatory discussions regarding a potential Phase 3 lupus program enriched for IFNGS-high patients. Key risks include the outcome of those regulatory interactions, potential financing or dilution needs, and the company's ability to differentiate envudeucitinib in an increasingly competitive oral TYK2 space that includes Bristol Myers Squibb's Sotyktu and Johnson & Johnson's Icotyde.
Trending AI Robots
For investors seeking a systematic edge across volatile names like ALMS, Tickeron's Trending AI Robots page highlights a curated selection of algorithmic trading strategies. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of automated approaches to explore. Consider reviewing the Trending AI Robots to see which strategies are currently outperforming.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
ALMS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ALMS turned positive on September 22, 2026. Looking at past instances where ALMS's MACD turned positive, the stock continued to rise in 17 of 18 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 21 of 29 cases where ALMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on ALMS as a result. In 27 of 39 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
Following a +5.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALMS advanced for three days, in 100 of 130 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ALMS entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.050) is normal, around the industry mean (26.780). P/E Ratio (0.166) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (123.457) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. ALMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement